TitleAssessing TP53 status in human tumours to evaluate clinical outcome.
Publication TypeJournal Article
Year of Publication2001
AuthorsSoussi T, Béroud C
JournalNature reviews. Cancer
Volume1
Pagination233–240
Date Publisheddec
Abstract

TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?

URLhttp://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11902578&retmode=ref&cmd=prlinks
DOI10.1038/35106009
PubMed ID11902578
cea
cnrs
inrae
inserm
logo-investissements